Taimerry Files IPO Prospectus: Light Aesthetics One-Stop Solution Provider Serving Over 10,000 Clinics with Tens of Millions in Revenue Within Two Years

“Serious medical care aims to treat diseases and save lives, so patients can tolerate certain side effects or adverse reactions; whereas light medical aesthetics serves healthy individuals seeking beauty enhancement, aiming to add perfection to an already good state, with virtually zero tolerance for adverse reactions.”Li Changchun, who has been deeply engaged in the field of serious medical care for over 20 years, shared with VCBeat his insights on transitioning into the light medical aesthetics sector. He believes that consumers’ zero tolerance for risk is “compelling the light medical aesthetics industry to establish a standard system even more rigorous than that of serious medical care.”

In 2000, Li Changchun graduated from Hefei University of Technology and later earned dual master’s degrees from Yangzhou University and Xiamen University. He spent over a decade deeply immersed in the pharmaceutical industry before serving as an executive at a leading Japanese dialysis device manufacturer and a British anesthesia equipment company. During his tenure at Qiaoying Capital, a USD-denominated private equity fund, he gained exposure to the medical aesthetics sector. Recognizing the technological dividends and compliance-driven opportunities within the non-surgical medical aesthetics segment, he decided to pivot his career.

At the end of 2022, Li Changchun joined forces with a close friend who had serially launched ventures in the field of minimally invasive surgery to co-found Changzhou Timerein Biotechnology Co., Ltd. (hereinafter referred to as “Timerein”), with the ambition of becoming the leading provider of one-stop solutions for light medical aesthetics in China.

Timerein maintains a comprehensive layout across the entire process of minimally invasive aesthetic procedures, including pre-procedure, intra-procedure, and post-procedure stages. WithInjection Consumablesas the foundation,Functional Regenerative MaterialswithPhotoelectric Devicesas the growth engine, with product coveragePreoperative (lidocaine-prilocaine cream), intraoperative (9-pin/5-pin needle heads, sharp/blunt needles, dermarollers, first-generation mesotherapy devices and second-generation mesotherapy robots, etc.,and those under development and registrationRecombinantCollagen and Hydroxyapatite Injectable Productsetc.),Postoperative Repair（RecombinantCollagen Dressings, Sprays, and GelsWait）To date, it has obtained 13 registration certificates for Class II and Class III medical devices, and is expected to secure medical device registration certificates for nearly ten additional products by the end of 2025.

In addition, Timerein boasts over 5,000 square meters of Class 10,000 and Class 100,000 cleanrooms, a 1,000-square-meter professional laboratory, a pilot-scale base for recombinant collagen under Class C+A conditions, and fully automated production lines.

Timerein Product Overview

“Light medical aesthetic injection consumables possess the dual attributes of high-frequency consumption and inelastic demand; product quality and pipeline layout determine a company’s core competitiveness.”When asked why Timerein chose to enter the market through injectable consumables for minimally invasive aesthetic procedures, its founder Li Changchun cited three reasons: first, the core team members have production experience with complex devices and consumables at MicroPort; second, Timerein is based in Changzhou, located in the Yangtze River Delta region, which boasts a mature medical device supply chain; and third, compliant injectable consumables were scarce at that time.

More critically, as the foundational support for minimally invasive aesthetic services, medical consumables are characterized by high-frequency, inelastic demand. This implies that establishing a moat built on “premium quality and comprehensive product offerings” enables a company to seize the strategic high ground in the market. For Timerein, entering the market through injectable consumables for minimally invasive aesthetics is not only a pragmatic choice to rapidly generate cash flow but also a strategic lever to break through market barriers and elevate its brand.

Timerein's Calibrated 9-Needle Set

Taking Timerein’s nine-needle device, which currently holds the highest market share, as an example. During the period when industry standards were lacking, the market was flooded with unlicensed gray-market products. Only a few Korean manufacturers produced nine-needle devices with Class III medical device certification, making them extremely scarce. Furthermore, leakage and pain were common issues associated with nine-needle products at that time. Addressing these pain points, Timerein’s independently developed nine-needle device, which has obtained NMPA Class III certification, achieved three major breakthroughs—

• First, precision design,34G/32G/30G multi-gauge needles with optimized insertion angles for smaller wounds and reduced pain;

• Second, precise volume control,Adjustable needle length ensures accurate injection depth, providing smooth operation with no leakage;

• Third, it is equipped with eight fully automated production lines.Ensuring consistency and stability in product quality, with an annual production capacity of 8 million acupuncture needles and 30 million injection needles.

“We are the manufacturer with the most comprehensive range of compliant licenses in China’s minimally invasive aesthetic injection consumables sector, and we also lead the field in intelligent manufacturing,” Li Changchun proudly told VCBeat, leveragingCompliant, High-Quality, Comprehensive Product Range, Timerein has within two years alreadyMylike, Langzi, Beauty Farm, One Plus One, Zhi Mei Yan Heand other medical aesthetics institutionsEstablished a partnership and joined forcesSinopharm, Jointown, and other distributorsCo-Expand the Market,Serving over 10,000 medical aesthetic institutions across China.

And just this May,Timerein Successfully Passes EU MDR On-site Audit, paving the way for its global strategy.

MDR On-Site Audit

Timerein, which has been rapidly advancing in the market for injectable consumables used in minimally invasive aesthetic procedures, has not rested on its laurels but continues to expand its offerings across the pre-operative, intra-operative, and post-operative stages of “minimally invasive aesthetics.”

“Medical aesthetics consumables are the foundation, while synthetic biology technology is the future.””Based on this assessment, Timerein has also expanded into the field of functional regenerative materials, holding key assets such as Type I/III/XVII collagen and hydroxyapatite.

Timerein UtilizationIntegration of the AlphaFold AI Model with Pharmacology, selecting the most effective functional groups from massive sequences and combining them with stable, highly expressed functional fragments to construct safer humanized collagen structures. On this basis, through sequence design and promoter optimization, the risk of sensitization caused by contaminating proteins or structural instability was avoided, resulting in the preparation of100% humanized, high-activity site, high stability and low lethality recombinant humanized collagen raw materials.

To meet diverse needs, Timerein has also developed two high-efficiency recombinant expression systems based on Pichia pastoris and Escherichia coli, achieving pilot-scale mass production of recombinant humanized Type III and Type XVII collagen, andA library of humanized collagen sequences with over 30 different molecular weights (covering functional fragments from 10 kDa to full-length sequences), laying the foundation for product iteration and pipeline expansion.

It is reported that the company has established and is operating two large-scale GMP-compliant production lines with capacities of 1,000 L and 3,000 L, possessing the capability to produce ton-level quantities of high-purity medical-grade recombinant humanized collagen annually. Meanwhile, based on this raw material, the company has developed products such as sterile liquid dressings, lyophilized fibers, sterile adhesive dressings, sprays, and gel dressings, andDevelopment of Class III medical aesthetic implants has been initiated.

Timerein's Partially Recombinant Collagen Products

To slow down the degradation rate of recombinant collagen and enhance its efficacy and longevity, Timerein has developed a hydroxyapatite composite technology. This technology organically combines hydroxyapatite with type I collagen in a non-free state using biomineralization techniques, making it suitable for bone defect filling and repair in fields such as dentistry and plastic surgery.

As a one-stop service provider for non-surgical medical aesthetics, Timerein has also developed lidocaine and prilocaine cream for the pre-procedure phase.

Anesthetics and topical anesthetic creams are essential consumables in medical aesthetic procedures. Topical anesthetics are required for a wide range of treatments, including minimally invasive plastic surgery, energy-based device therapies, mesotherapy injections, and semi-permanent makeup. While lidocaine, commonly available on the market, has a rapid onset of action, its duration of effect is limited. Timerein has developed a lidocaine and prilocaine cream by combining lidocaine with prilocaine (which has a slower onset but a longer duration of action). The synergistic effect of these two ingredients provides local anesthesia for skin and mucous membranes, reducing or eliminating local pain perception and enhancing the overall treatment experience.It is reported that the product will be launched in late 2025.

Additionally, the company’s second-generation hydro-lifting robot has also been approved for market launch, and itsVoice interaction functionality has been implemented, effectively preventing potential cross-contamination that may occur when operators alternate between touching the screen and performing facial procedures.Meanwhile, the product also intelligently stores and analyzes users’ historical data, continuously tracking changes in skin condition and treatment efficacy.

Timerein First-Generation Hydro-Lifting Device

Timerein centers on light medical aesthetics, spanning three major sectors: injectable consumables, functional regenerative materials, and photoelectric devices, thereby establishing full-industry-chain capabilities from upstream raw materials to end-user equipment. Such a strategic layout is uncommon in the medical aesthetics industry, as most companies focus on a single sector, making comprehensive enterprises like Timerein relatively rare.

How does Timerein sustain such a comprehensive and extensive operational scope, and how are resources allocated? Li Changchun stated that while Timerein’s business appears diverse, it is in fact tightly centered around non-surgical aesthetic medicine. The company adopts an Amoeba management model, organized into three independent divisions—the Raw Materials Division, the Consumables Division, and the Production and Operations Division—each operating with decentralized authority.

Compared with other medical aesthetics companies that focus on a specific field (such as collagen or optoelectronic devices), Timerein has three additional advantages:

• First, a full-chain layout in light medical aesthetics.Timerein avoids competing on single products, instead entering the market as a one-stop service provider for non-surgical aesthetic medicine. In the short term, the company does not seek to be the “first” or “pioneer” in any specific field, but rather focuses on integrating resources to deliver comprehensive solutions for non-surgical aesthetic treatments.

• Second, the advantage of cost-effectiveness.For specific individual products, companies are committed to achieving greater cost-effectiveness by placing greater emphasis on price competitiveness and quality assurance to attract more customers.

• Third, dynamic portfolio competition strategy.Drawing on the "Tian Ji Horse Racing" strategy, we employ a combination of product offerings to respond to market changes, diversify risks, and enhance overall competitiveness.

Li Changchun Outlines a Clear Three-Stage Leapfrog Strategy Blueprint for Timerein—1.0 Era: Centered on a “Comprehensive Portfolio of Consumables”, now basically completed;2.0 Era Focuses on Functional Regenerative Materials,Related products are in the final countdown to market launch;3.0 Era Will Extend into the Field of Implantable Agents, focusing on expanding its portfolio of collagen-based filler gels and hydroxyapatite products, and strengthening Timerein’s positioning as a one-stop service provider for minimally invasive aesthetic medicine through technological barriers and product line extension.

These advantages and plans have also been fully recognized by the market, Timerein’s Report CardImpressive— In just two and a half years, the company obtained 13 medical device registration certificates, including four Class III and nine Class II products; served over 10,000 medical aesthetic institutions across China; achieved significant breakthroughs in its collagen raw material pipeline; and generated annual revenue exceeding tens of millions of RMB within three years of operation. With the approval and market launch of products such as hydroxyapatite, Timerein is poised to reach new heights.

Finally, addressing the continuous emergence of new raw materials in the medical aesthetics sector, Li Changchun noted that product iteration and upgrading are processes common to all industries. However, different raw materials each have their own strengths, often serving complementary rather than directly competitive roles. For instance, hyaluronic acid demonstrates significant hydrating effects, while collagen offers superior performance as a dermal filler. The key lies in supplementing products based on their intended uses; maximizing efficacy for these intended applications constitutes a company’s core competitiveness.

Jiangsu Wujin Economic Development Zone (Changzhou West Taihu Science and Technology Industrial Park) is located at the geometric center of Changzhou, where the metropolitan circles of Shanghai, Nanjing, and Hangzhou converge. It serves as a key platform within the Southern Jiangsu National Independent Innovation Demonstration Zone and stands as the primary stronghold for Changzhou’s strategic initiative to build the “Central Axis Hub of the Yangtze River Delta” during the 14th Five-Year Plan period. The park vigorously develops its “One High, Four New” industrial sectors—namely high-end medical health, new materials, new energy, intelligent manufacturing, and the new economy—while strategically laying out four future industries: Changzhou Hydrogen Bay, Oriental Carbon Valley, Cell Technology Port, and Synthetic Biology Island. In the realm of high-end medical health, the park has successfully established the National International Innovation Park for Medical Devices, the National Base for Transformation and Upgrading of Pharmaceutical Foreign Trade, and the Cross-Strait (Changzhou) Health Industry Cooperation Zone. By aggregating more than 400 R&D, manufacturing, and service enterprises, the park assumes a leading role in driving industrial advancement.